Digital and Coaching Interventions for Uptake of Cancer Genetic Testing: The MiGHT Randomized Clinical Trial

Importance: Germline genetic testing (GT) for hereditary cancer risk can inform cancer treatment, screening, and prevention, yet testing rates remain low. Alternative strategies are needed to improve facilitation of GT.

Objective

To compare 2 patient-level interventions to increase uptake of hereditary cancer GT against usual care. Design, setting, and participants: The Michigan Genetic Hereditary Testing (MiGHT) randomized clinical trial analyzed self-reported GT outcome data from participants meeting clinical GT criteria between April 21, 2022, and November 21, 2025. Participants were adults (age ≥18 years) who met national criteria for genetic evaluation and had not previously completed germline GT recruited from oncology, primary care, and gastroenterology practices; research registries; and the general public in Michigan. Data were analyzed from April 30, 2025, to May 1, 2026.